If you would like to be placed into our database and be notified of any future trials we may be in a position to conduct, please provide us with your contact information and what type(s) of indication(s) you might be interested in participating in or learning more about.
Alzheimer’s disease is an incurable disease that, over time, progressively leads to a loss of memory and independent functioning. It can also be extremely burdensome to family members and caregivers. Currently, there is no known cure for this disease. While there are a number of drugs approved by the FDA to treat this disease, as a class, they only provide short-term, and woefully limited symptomatic relief. The industry and the medical community alike clearly recognize that better treatments are needed that are not only able to significantly affect the key symptomatology of the disease, but also its underlying disease process.
To this end, SPRI is currently engaged in a number of industry-sponsored clinical research trails aimed at attempting to determine the safety and effectiveness of new medications or medication approaches that may have the potential of reducing the magnitude of the cognitive impairments associated with this devastating disease.
Are you or someone you know …
➢ Between the ages of 50 & 85,
➢ Experiencing memory problems or been diagnosed with probable Alzheimer’s disease, and
➢ Have a family member, close friend or caregiver who is willing to accompany you to study visits?
If so, you or that person may be eligible to participate in one of our clinical trials.
Participation is strictly confidential. Study medication, and study-related visits, procedures and tests are offered free of charge. We also offer limited financial compensation, as well as reimbursement to cover reasonable food and travel-related expenses.
To volunteer or learn more about what is involved in participating in one of these clinical trials or to see if you qualify to participate, please call 718-616-2400 or click the Contact US button below to send us an email.